News

Professional cardiovascular societies and many working cardiologists question the U.S. Food and Drug Administration’s (FDA’s) recent recommendation that patients undergo genetic testing before...

A new study demonstrated that some patients may not need to receive prolonged anti-clotting therapy after drug-...

cath lab clinical trial study pharmaceuticals antiplatelet therapy arctic

Patients who do not experience a major cardiac event in the first year after receiving drug-eluting stent (DES) may not need to receive prolonged dual ...

xience prime xpedition V antiplatelet stents eluting clinical trial study cath

Abbott announced it plans to initiate a randomized, controlled trial in the United States to evaluate the use...

PDI, Inc. and Transgenomic, Inc. announced the signing of a U.S. collaboration agreement to commercialize CardioPredict, a molecular diagnostic test developed by Transgenomic. CardioPredict is a...

Icahn School of Medicine at Mount Sinai PARIS Study Antiplatelet Therapy PCI

Lead study investigators from Icahn School of Medicine at Mount Sinai presented their Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) study findings at the ESC...

Aggredyne Inc., has received ISO 13485 certification for its quality control program related to the manufacture of the AggreGuide family of platelet function analyzers.

Decision Resources forecasts that Bayer/Janssen's Xarelto will be the sales-leading therapy among the novel oral anticoagulants in the combined venous thromboembolism (VTE) markets. Xarelto...

Atherotech Diagnostics Lab has added three new genetic tests to its cardiometabolic test offering: warfarin sensitivity, Plavix sensitivity and the thrombophilia risk test.

 

Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non–ST-segment elevation...

September 5, 2013 — ITC Nexus Holding Co., a company in hemostasis management and point-of-care (POC) testing, announced it has acquired Accumetrics, a specialist in assessing patient response to...

August 5, 2013 — AstraZeneca announced results from a new sub-analysis of the PLATO study that evaluated the incidence of stent thrombosis in patients with acute coronary syndrome (ACS).

Merck announced that the New Drug Application (NDA) for its investigational anti-thrombotic medicine, vorapaxar, has been accepted...

T2 Biosystems announced the presentation of data strongly correlating T2Hemostat results with patients’ clinical outcomes. In 26 patients who presented with chest pain and underwent cardiac...

July 15, 2013 — Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental new drug application (sNDA)...

Clinical Study Aspirin Duke Medicine Blood Test Platelet Functioning Testing

Aspirin has been widely used for more than 50 years as a common, inexpensive blood thinner for patients with heart disease and stroke, but doctors have little understanding of how it works and why...

University of Maryland Medical Center Genetic-Testing Program Cardiac Stent

Patients with coronary artery disease who undergo treatment at the University of Maryland Medical Center (UMMC) now can receive long-term therapy based on information found in their genes. As part...

The U.S. Food and Drug Administration approved Kcentra (prothrombin complex concentrate, human) for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major...